drugset
drugset / Trial / NCT00576108

A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)

NCT00576108 ↗

Phase 2 Completed 48 enrolled Kalypsys, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of 2 weeks of topical KD7040 versus placebo in the treatment of postherpetic neuralgia.

Timeline

Start
2007-11
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject KD7040 Small molecule — Topical

Indications

herpes zoster neuropathy, painful postherpetic neuralgia